TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Low-dose IL-2( Interleukin-2) Treatment in SLE

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the American College of Rheumatology criteria for the diagnosis of SLE.~* Under standard treatment (≥ 2 months) at the time of inclusion~* Background treatment failed to control flares or to permit prednisone tapering~* With at least one of the following manifestations: thrombocytopenia, disease-associated rash, mouth ulcer, non-infectious type of fever, active vasculitis, renal disorder(proteinuria\>0.5g/day), neuropsychiatric SLE.~* Positive for at least one of the following laboratory tests: ANA\>1:160, anti-dsDNA, immunoglobulin\>20g/L, decreased C3 or C4, leukopenia\<3×10\^9/L, thrombocytopenia\<100×10\^9/L;~* SLE disease activity index(SLEDAI) ≥ 8.~* Negative HIV test.~* Negative for hepatitis B and C virus.~* Written informed consent form.~Exclusion Criteria:~* Sever chronic liver, kidney, lung or heart dysfunction; (heart failure (≥ grade III NYHA), hepatic insufficiency (transaminases\> 3N) )~* Serious infection such as bacteremia, sepsis;~* Cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or Basocellular carcinoma);~* High-dose steroid pulse therapy (\>1.5mg/kg) or IV bolus of corticosteroids in the last 2 months.~* History of administration of rituximab or other biologics;~* Purified protein derivative (tuberculin) \>10mm~* Mental disorder or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give information;~* Inability to comply with IL-2 treatment regimen.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Interleukin-2 (Type: EXPERIMENTAL): Interleukin-2 to treat activated SLE.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has type 2 diabetes mellitus (T2DM)~* Patient is 18 years of age (or older)~* Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period~Exclusion Criteria:~* Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis~* Patient required insulin within the prior 8 weeks~* Patient is on a weight loss program and is not in the maintenance phase~* Patient started on a weight loss medication (e.g., orlistat or sibutramine) within the prior 8 weeks~* Patient is on or likely to require treatment with treatment with immunosuppressive agents (e.g., cyclosporin, methotrexate)~* Patient has cirrhosis, active liver disease (other than fatty liver) or symptomatic gallbladder disease~* Patient has chronic myopathy, or a progressive neurological or neuromuscular disorder (e.g., multiple sclerosis or polymyositis)~* Patient has any of the following disorders within the past 6 months:~Acute coronary syndrome (e.g., MI or unstable angina), Coronary artery intervention, Stroke or transient ischemic neurological disorder.~* Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months~* Patient has severe peripheral vascular disease~* Patient has congestive heart failure~* Patient is HIV positive~* Patient has a clinically important hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)~* Patient has a history of neoplastic disease~* Patient has a history of alcohol or drug abuse within the past 3 years~* Patient has viral hepatitis (hepatitis B or C)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin 100 mg (Type: ACTIVE_COMPARATOR): Sitagliptin 100 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~- Male or female patient \<60 years old with relapsing multiple sclerosis (RMS) either treated for at least 6 months with 7 or 14 mg teriflunomide in one of the studies LTS6048 or LTS6050, or treated with a stable dose of interferon-β-1 for at least 6 months.~Exclusion Criteria:~* Concomitant infectious pathology at the time of vaccination;~* MS relapse within 1 month before vaccination;~* Systemic corticosteroids within 1 month before the vaccination;~* Any contraindication to influenza vaccine;~* Any vaccination within the last 6 months;~* Prior use of any investigational drug or participation to a clinical trial within 1 year (only for patients under interferon-β-1);~* Prior or concomitant use (for a minimum of 1 year before study entry) of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate, mycophenolate, natalizumab (Tysabri®), leflunomide or fingolimod or other immunomodulator/immunosuppressant in development;~* Prior or concomitant use of glatiramer acetate within 1 year before study entry;~* Prior or concomitant use of intravenous immunoglobulins within 3 months before study entry;~* Pregnant or breast feeding women;~* Woman of childbearing potential without adequate contraception.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- Teriflunomide 7 mg (Type: EXPERIMENTAL): Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months
- Teriflunomide 14 mg (Type: EXPERIMENTAL): Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months
- IFN-β-1 (Type: ACTIVE_COMPARATOR): Influenza vaccine in participants treated with a stable dose of Interferon-β-1 (IFN-β-1) for at least 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age above or equal to 19 years at the time of Ryzodeg® initiation~* Type 2 diabetes mellitus patients~* Treated with any basal-insulin (plus/minus OAD (Oral Antidiabetic Drug)) or premix-insulin (plus/minus OAD) for at least 26 weeks prior to switching to Ryzodeg®~* Treated with Ryzodeg® (plus/minus OAD) for at least 26 weeks after switch from any basal insulin (plus/minus OAD) or premix insulin (plus/minus OAD)~* At least more than once documented medical visit for 26weeks (plus/minus 6 weeks) after Ryzodeg® initiation~* Minimum available data : age, type of diabetes at the time of Ryzodeg® initiation, HbA1c \[Three values: most recent value within 26 weeks (plus/minus 6 weeks) prior to Ryzodeg® initiation, a value of Ryzodeg® initiation date (plus/minus 6 week), and a value in the first 26 weeks (plus/minus 6 weeks) after Ryzodeg® initiation\]~* The decision to treat with Ryzodeg® was taken by treating physician independently from decision to include patient in study.~Exclusion Criteria:~* Patients treated with any diabetic investigational drug within 26 weeks before or after the initiation of Ryzodeg®~* Patients switching to Ryzodeg® below 26 weeks prior to the data collection date~* Patients not treated with any basal-insulin or premix-insulin at least 26 weeks prior to receiving Ryzodeg®~* Patients treated by continuous subcutaneous insulin infusion prior to receiving Ryzodeg®~* Pregnancy patient~* Patients not treated with the local licensed Ryzodeg®

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Ryzodeg (Type: None): Patients treated with any basal-insulin or premix-insulin for at least 26 weeks prior to switching to Ryzodeg® and treated for at least 26 weeks after switching to Ryzodeg®.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Near Normalisation of BG Improves the Potentiating Effect of GLP-1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-70 years~* Type 2 diabetes diagnosed after 30 years of age~* BMI \> 25~Exclusion Criteria:~* Severe complications to diabetes~* Abnormal liver og kidney function~* Haemoglobin below the lower limit~* Macroalbuminuria~* Systemic disease~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- GLP-1 (Type: EXPERIMENTAL): A graded glucose infusion with an infusion of GLP-1 (1½ pmol/kg/min)
- Saline (Type: EXPERIMENTAL): A graded glucose infusion together with a continuous infusion of saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Non-CE Marked Intermittent Catheters for Females

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Minimum 18 years of age and with full legal capacity~* Daily intermittent catheterization for bladder management, with at least two catheters used on average pr. day, during the last 3 months~* Ability to self-catheterize~* Written informed consent, signed letter of authority and signed secrecy agreement given~Exclusion Criteria:~* Breastfeeding~* Pregnancy (based on pregnancy test - urine)~* Participation in any other clinical study during this investigation~* Symptoms of urinary tract infection as judged by the investigator~* Any know allergies towards ingredients in the products~* Relevant medical history that would prevent the subject from participation (investigators judgement)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intermittent catheter; SpeediCath® Standard female (Type: ACTIVE_COMPARATOR): Participants underwent two catheterizations with standard of care intermittent catheter: The first was performed by a trained nurse, the second by the participant later the same day.
- New intermittent catheter Variant 1 for females (Type: EXPERIMENTAL): Participants underwent two catheterizations with the new intermittent catheter variant 1 for females: The first was performed by a trained nurse, the second by the participant later the same day.
- New intermittent catheter Variant 2 for females (Type: EXPERIMENTAL): Participants underwent two catheterizations with the new intermittent catheter variant 2 for females: The first was performed by a trained nurse, the second by the participant later the same day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are at least 6 months old and weighing at least 15 kg.~* Infestation with head lice and viable nits.~* Are otherwise in a normal state of health.~* Willing and able to attend all study visits as scheduled.~* Agree not to cut or chemically treat their hair in the period between treatment and the final visit.~* The subject and/or his/her parent/legal guardian have provided written informed consent, and, if appropriate, the child has provided assent.~* Females of childbearing potential must have a negative urine pregnancy test at screening and agree to take reasonable precautions against becoming pregnant during the study period.~Exclusion Criteria:~* Subjects who have received any over the counter or prescription treatment for head lice in the last 2 weeks.~* Subjects unable to comply with the study obligations and all study visits.~* Subjects with eczema or other chronic conditions of the scalp and skin.~* Subjects in a household with more than 5 infested members.~* Subjects with a history of allergy to ivermectin or any ingredients commonly included in hair products such as shampoos, hair conditioners, or styling aids.~* Subjects with neurologic conditions including a seizure disorder or history of seizures.~* Subjects with an infestation of body lice or pubic lice (determined by questioning).~* Subjects suffering from a condition likely to require medical attention, including administration of oral or systemic antibiotics, oral or systemic corticosteroids, or any other treatment, which in the opinion of the Investigator and visiting physician could influence the results of the study.~* Subjects with other diagnoses which, in the opinion of the Investigator, would interfere with efficacy or safety assessments or would preclude study participation.~* Subjects with very short (shaved) hair.~* Subjects who have been treated with a systemic antibiotic within the previous 2 weeks before screening.~* Subjects who have been previously enrolled in any clinical study within the past 30 days; subjects may not participate in another study while participating in this study.~* Pregnant and/or nursing females.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.15% ivermectin (Type: EXPERIMENTAL): Participant on 0.15% ivermectin treatment conditioner
- 0.25% ivermectin (Type: EXPERIMENTAL): Participants on 0.25% ivermectin treatment conditioner
- 0.50% ivermectin (Type: EXPERIMENTAL): Participants on 0.50% ivermectin treatment conditioner
- Placebo (Type: PLACEBO_COMPARATOR): participants on Placebo (Vehicle control)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate SYN115 in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Parkinson's disease~* Hoen and Yahr stage 1-3~* On stable dose of anti-parkinsons treatment for 30 days prior to screening~* Age 40 to 75 years~* Sign an IRB approved informed consent~* Men and women agree to use adequate birth control~* ECG measurements are within normal limits~* Able to understand study requirements~Exclusion Criteria:~* Secondary Parkinson's (drug induced or post stroke)~* Received treatment with other investigational drug 30 days prior to study entry~* Using disallowed medications~* Significant neurological illness other than Parkinson's~* IQ less than 70 on IQ test~* MMSE score \< or = 23~* History of psychosis or on anti-psychotic medication~* Current serious medical illness~* History of substance abuse~* History of head injury with loss of consciousness~* History of brain surgery~* Contraindications to MRI like claustrophobia, metal implants or other implantable devices~* Abnormal liver function tests and/or hepatitis or cholangitis~* Gilberts disease~* Pregnant or nursing~* Known hypersensitivity to SYN115

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Active medication Tozadenant 20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
- 2 (Type: PLACEBO_COMPARATOR): Crossover from arm 1 to arm 2 with one week washout. One of the arms is placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory with osteoporosis~* Hip or spine bone mineral density (BMD) measurement more than 2.5 standard deviations below the average bone mass of young healthy women or more than 2.0 standard deviations in women who have a history of a vertebral or nonvertebral fragility fracture.~Exclusion Criteria:~* Diseases of bone other than osteoporosis~* Treatment with estrogens in the 3 months prior to enrollment or for more than 2 months in the past year~* Treatment with oral bisphosphonates in the 3 months prior to enrollment or for more than 2 months in the past year; treatment with intravenous bisphosphonates in the 12 months prior to enrollment~* Increased risk for the development of osteosarcoma

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Teriparatide (Type: EXPERIMENTAL): Participants receive teriparatide 20 microgram once daily by subcutaneous injection for 18 months followed by 6 months off therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Young Adult Congenital Heart Disease Physical Activity Lifestyle Study (YACHD-PALS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Between the ages of 18-25 (if 18, must no longer be in high school and no longer living at home)~2. Are diagnosed with moderate or complex structural congenital heart disease~3. Live within 120 miles of Nationwide Children's Hospital~Exclusion Criteria:~1. Do no speak or write proficiently in English~2. Have cognitive impairments that would interfere with the completion of study procedures~3. Are diagnosed with a genetic syndrome (e.g., Downs, Marfans)~4. Have been engaged in a formal exercise program within the past 6 months~5. Underwent open-heart surgery or have had a transcatheter valve replacement in the last 3 months~6. Are otherwise prohibited by their cardiologist to engage in at least moderate levels of physical activity~7. Are unable to complete a treadmill-based exercise stress test~8. Are currently pregnant~9. Have contraindications for exercise based on an exercise stress test (e.g., exercise-induced arrhythmias or evidence of cardiac ischemia)~10. \>150 min/weekday of moderate-to-vigorous physical activity per the accelerometer~11. Do not have access or a device for videoconferencing with the coach

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Fitbit Only (Type: ACTIVE_COMPARATOR): In the Fitbit Only arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, and a Fitbit. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
- Fitbit + Coaching Sessions (Type: EXPERIMENTAL): In the Fitbit + Coaching Sessions arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, a Fitbit, and will have 8 sessions with a coach (interventionist) over the course of 20 weeks. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low-dose S-ketamine and Dexmedetomidine in Combination With Opioids for Postoperative Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years old, body weight ≥ 40 kg;~* Scheduled to undergo scoliosis correction with pedicle screw fixation;~* Planned to use patient-controlled intravenous analgesia after surgery.~Exclusion Criteria:~* Refused to participate in the study;~* Preoperative sick sinus syndrome, severe sinus bradycardia (heart rate \< 50 beats/min), atrioventricular block grade II or above without pacemaker; or comorbid with congenital heart disease, arrhythmia, or other serious cardiovascular diseases with a cardiac function grade ≥ III;~* Patients with obstructive sleep apnea syndrome, or a STOP-Bang score ≥ 3 in combination with a serum HCO3- level ≥ 28 mmol/L;~* History of hyperthyroidism and pheochromocytoma;~* History of schizophrenia, epilepsy, myasthenia gravis, or delirium;~* Severe liver dysfunction (child Pugh grade C), severe renal dysfunction (preoperative dialysis), or American Society of Anesthesiologists grade ≥ IV;~* Barrier in communication;~* Other conditions that are considered unsuitable for study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combined analgesia group (Type: EXPERIMENTAL): Patient-controlled analgesia is established with S-ketamine 50 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lock-out interval of 8 minutes and a background infusion rate at 1 ml/h.
- Control group (Type: PLACEBO_COMPARATOR): Patient-controlled analgesia is established with sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lock-out interval of 8 minutes and a background infusion rate at 1 ml/h.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete